Vical

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Vical sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 10 completed early-phase tilt top decile by trial count

Vical: 13 sponsored US clinical trials, none currently recruiting.

Vical sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 3 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malignant Melanoma, with 1 trials.

Top-decile sponsor footprint

Vical ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 32/100

10 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

TERMINATED Phase 2

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

NCT03327727
COMPLETED Phase 2

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

NCT02837575
COMPLETED Phase 1

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

NCT02030301
COMPLETED Phase 1

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

NCT00694213
COMPLETED Phase 1

Pandemic Influenza Plasmid DNA Vaccines (Needle)

NCT00709800
COMPLETED Phase 3

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

NCT00395070
COMPLETED Phase 1

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

NCT00223899
COMPLETED Phase 2

Phase II Trial of Allovectin-7® for Metastatic Melanoma

NCT00044356
TERMINATED Phase 1

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

NCT00005072
TERMINATED Phase 2

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00004050
COMPLETED Phase 2

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00003646
COMPLETED Phase 3

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00003647
COMPLETED Phase 3

Phase II Trial of Allovectin-7® for Head and Neck Cancer

NCT00050388

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 5
Phase 3 3

Therapeutic Areas

Malignant Melanoma 1
Skin Cancer 1
Metastatic Melanoma 1
Melanoma 1

How the Vical early-phase archive is shaped

13 indexed studies, none listed as recruiting (0% open); 10 completed (77%).

Phase mix: 3 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Malignant Melanoma (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Vical: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Vical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share VicalAdaptimmuneAgennixAkili Interactive LabsAlumis10xBio22nd Century Group23andMe3-C Institute for Social Development
Vical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Vical page

13 registered trials is a research-attention snapshot, not an endorsement of Vical or any single study.

  • None of Vical's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Malignant Melanoma is the condition Vical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malignant Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Vical pipeline card: 13 registered trials from official public datasets.Report a data error.